Fatima T, Mubasher M, Rehman H, Niyazi S, Alanzi A, Kalsoom M
AMB Express. 2024; 14(1):91.
PMID: 39133343
PMC: 11319546.
DOI: 10.1186/s13568-024-01747-8.
Brown J, Spielmann G, Yang S, Compton S, Jones L, Irwin M
J Cachexia Sarcopenia Muscle. 2024; 15(4):1520-1527.
PMID: 38887915
PMC: 11294014.
DOI: 10.1002/jcsm.13509.
Yadav R, Schubbert S, Holder P, Chiang E, Kiabi N, Bogaert L
Front Pharmacol. 2024; 15:1380000.
PMID: 38887559
PMC: 11181026.
DOI: 10.3389/fphar.2024.1380000.
Cini J, Dexter S, Rezac D, McAndrew S, Hedou G, Brody R
Front Immunol. 2024; 14:1326927.
PMID: 38250068
PMC: 10798159.
DOI: 10.3389/fimmu.2023.1326927.
Luo M, Gong W, Zhang Y, Li H, Ma D, Wu K
Cell Commun Signal. 2023; 21(1):347.
PMID: 38049832
PMC: 10694921.
DOI: 10.1186/s12964-023-01354-3.
Immunomodulation with IL-7 and IL-15 in HIV-1 infection.
Gunst J, Goonetilleke N, Rasmussen T, Sogaard O
J Virus Erad. 2023; 9(3):100347.
PMID: 37767312
PMC: 10520363.
DOI: 10.1016/j.jve.2023.100347.
The role of interleukin-15 in the development and treatment of hematological malignancies.
Sindaco P, Pandey H, Isabelle C, Chakravarti N, Brammer J, Porcu P
Front Immunol. 2023; 14:1141208.
PMID: 37153603
PMC: 10157481.
DOI: 10.3389/fimmu.2023.1141208.
IL-15 Superagonist N-803 Enhances IFN-γ Production of MAIT Cells in SIV Macaques.
Ellis-Connell A, Balgeman A, Kannal N, Hansen Chaimson K, Batchenkova A, Safrit J
Infect Immun. 2022; 90(10):e0025922.
PMID: 36190256
PMC: 9584292.
DOI: 10.1128/iai.00259-22.
A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities.
Lv L, Wang H, Shi W, Wang Y, Zhu W, Liu Z
Appl Microbiol Biotechnol. 2022; 106(21):7039-7050.
PMID: 36184689
DOI: 10.1007/s00253-022-12209-1.
Interleukin 15 in Cell-Based Cancer Immunotherapy.
Zhou Y, Husman T, Cen X, Tsao T, Brown J, Bajpai A
Int J Mol Sci. 2022; 23(13).
PMID: 35806311
PMC: 9266896.
DOI: 10.3390/ijms23137311.
A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells.
Li Y, Wu L, Liu Y, Ma S, Huang B, Feng X
Transl Oncol. 2022; 21:101424.
PMID: 35477065
PMC: 9136603.
DOI: 10.1016/j.tranon.2022.101424.
Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
Miljkovic M, Dubois S, Muller J, Bryant B, Ma E, Conlon K
Blood Adv. 2022; 7(3):384-394.
PMID: 35475910
PMC: 9898617.
DOI: 10.1182/bloodadvances.2021006440.
IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
Chen W, Bamford R, Edmondson E, Waldmann T
Clin Cancer Res. 2022; 28(10):2082-2093.
PMID: 35262675
PMC: 10569074.
DOI: 10.1158/1078-0432.CCR-21-0496.
A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky J, Chen W, Dubois S, Daenthanasanmak A, Muller J, Reid R
J Immunother Cancer. 2022; 10(1).
PMID: 35101947
PMC: 8804710.
DOI: 10.1136/jitc-2021-004104.
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy.
Smith P, Piadel K, Dalgleish A
Vaccines (Basel). 2021; 9(12).
PMID: 34960140
PMC: 8708201.
DOI: 10.3390/vaccines9121392.
Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies.
Bernstein Z, Spangler J
J Clin Invest. 2021; 131(19).
PMID: 34596048
PMC: 8483744.
DOI: 10.1172/JCI152857.
Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection.
Harwood O, OConnor S
Viruses. 2021; 13(9).
PMID: 34578331
PMC: 8473246.
DOI: 10.3390/v13091750.
Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma.
Hsu F, Liu Y, Tsai C, Yueh P, Chang C, Lan K
Cancers (Basel). 2021; 13(8).
PMID: 33918641
PMC: 8070266.
DOI: 10.3390/cancers13081789.
Heterodimeric IL-15 in Cancer Immunotherapy.
Bergamaschi C, Stravokefalou V, Stellas D, Karaliota S, Felber B, Pavlakis G
Cancers (Basel). 2021; 13(4).
PMID: 33671252
PMC: 7922495.
DOI: 10.3390/cancers13040837.
IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S, Smeltz R, Nanajian A, Heller R
Front Immunol. 2021; 11:614667.
PMID: 33628206
PMC: 7897681.
DOI: 10.3389/fimmu.2020.614667.